ILU Stock Chart & Stats
€190.56
€0.74(0.60%)
At close: 4:00 PM EDT
€190.56
€0.74(0.60%)
Day’s Range― - ―
52-Week Range€77.67 - €196.70
Previous CloseN/A
Volume243.00
Average Volume (3M)120.00
Market Cap
€26.19B
Enterprise Value€28.37K
Total Cash (Recent Filing)€1.17B
Total Debt (Recent Filing)€2.53B
Price to Earnings (P/E)38.2
Beta0.45
Next Earnings
Oct 29, 2026EPS Estimate
1.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.41
Shares Outstanding151,000,000
10 Day Avg. Volume163
30 Day Avg. Volume120
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)7.65
Price to Sales (P/S)4.81
P/FCF Ratio22.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€172.57Price Target Upside-9.44% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering17
EPS Forecast (FY)4.6
Revenue Forecast (FY)€3.98B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelIllumina’s installed-base model creates recurring consumables revenue after instruments are placed, linking future sales to customer utilization and sequencing throughput. This can improve revenue visibility and deepen workflow retention as clinical and research customers continue operating established platforms.
Strong Profitability And Cash GenerationThe recovery has produced substantial operating profitability and cash generation, giving Illumina internal resources to support product development, customer adoption and capital allocation. High margins and strong free cash flow also provide a durable buffer against operating variability over the next several quarters.
NovaSeq X Adoption And Raised OutlookElevated NovaSeq X placements and a growing installed base should support consumables pull-through into 2027, while raised revenue and EPS guidance indicates improving execution. The shift toward clinical volumes on X strengthens the platform’s role in higher-growth sequencing applications.
Bears Say
Research Consumables WeaknessPersistent weakness in research and applied consumables limits the benefits of clinical growth and directly pressures utilization of Illumina’s sequencing installed base. Management’s expectation for continued declines suggests this is more than a single-quarter issue and may restrain near-term revenue mix.
Earnings Durability Remains UncertainThe sharp swing from significant losses to current profitability demonstrates that earnings have not yet followed a consistently stable path. Such volatility makes future margins and cash conversion less predictable, particularly if sequencing demand or customer funding weakens again.
Leverage And Financing BurdenModerate-to-elevated leverage reduces financial flexibility relative to the current profitability profile and leaves more cash flow committed to debt obligations. If operating performance softens, the balance sheet could constrain investment, shareholder returns and the ability to absorb another weaker earnings cycle.
Illumina News
ILU FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was €77.67 and its highest was €196.70 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is €26.19B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Oct 29, 2026 which is in 46 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Jul 30, 2026. The company reported €1.126 earnings per share for the quarter, beating the consensus estimate of €1.054 by €0.072.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Overvalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.17.
How many shares outstanding does Illumina have?
Illumina has 151,000,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of €1.126 in its last earnings report, beating expectations of €1.054. Following the earnings report the stock price went down -1.692%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in DE:ILU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Illumina Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€172.57 (-9.44% Downside)
€172.57 (-9.44% Downside)
Blogger Sentiment
Bullish
DE:ILU Sentiment 64%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €375.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
107.88%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Illumina
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
ILU Company Deck
ILU Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive: Illumina delivered a quarter with strong top-line beats, materially higher instrument placements (especially NovaSeq X), margin outperformance, raised full-year guidance and strengthened multi-omics and BioInsight momentum (Billion Cell Atlas revenue and partners). Headwinds remain—memory and freight costs, inventory/tax timing impacts, and continued weakness in research consumables and some regions—but management has absorbed costs, secured supply, and raised guidance while reaffirming long-term targets. The positive operational and financial beats and the upgraded outlook outweigh the listed challenges.View all DE:ILU earnings summariesILU Revenue Breakdown
74.30% Consumables
11.10% Instruments
14.60% Service and other revenue
ILU Stock 12 Month Forecast
Average Price Target
€172.57
▼(-9.44% Downside)